# Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic (PK/PD) Profile of ACT100 in Healthy Participants..

> **NCT07408908** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Xiamen Amoytop Biotech Co., Ltd.** · enrollment: 48 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus
- Cutaneous Lupus Erythematosus

## Interventions

- **DRUG:** ACT100 Injection
- **DRUG:** Placebo for ACT100
- **DRUG:** ACT100 Injection
- **DRUG:** Placebo for ACT100
- **DRUG:** ACT100 Injection
- **DRUG:** Placebo for ACT100
- **DRUG:** ACT100 Injection
- **DRUG:** Placebo for ACT100
- **DRUG:** ACT100 Injection
- **DRUG:** Placebo for ACT100
- **DRUG:** ACT100 Injection
- **DRUG:** Placebo for ACT100

## Key facts

- **NCT ID:** NCT07408908
- **Lead sponsor:** Xiamen Amoytop Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-06
- **Primary completion:** 2027-03-30
- **Final completion:** 2027-10-30
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-02-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07408908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07408908, "Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic (PK/PD) Profile of ACT100 in Healthy Participants..". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07408908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*